Fredun Pharmaceuticals Limited has notified the BSE of an upcoming board meeting scheduled for Monday, May 25, 2026, in accordance with Regulation 29 read with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation, dated May 15, 2026, was submitted by Director Fredun Nariman Medhora (DIN: 01745348).

Key Agenda Items

The board meeting has been convened to deliberate on several significant matters pertaining to the financial year ended March 31, 2026. The following items are on the agenda:

Trading Window Closure

In compliance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in securities of Fredun Pharmaceuticals shall remain closed until the expiry of 48 hours after the declaration of the financial results. Market participants and insiders are advised to take note of this restriction accordingly.

Regulatory Compliance

The board meeting intimation has been filed in accordance with applicable SEBI listing regulations. The notice was digitally signed by Director Fredun Nariman Medhora on May 15, 2026, at 11:37:00 IST, confirming the company's adherence to disclosure requirements under the applicable regulatory framework.

Fredun Pharmaceuticals Limited has announced the opening of a new manufacturing facility in Palghar, Maharashtra, representing a significant milestone in the company's expansion strategy. The facility marks the addition of the company's fifth manufacturing unit and demonstrates its commitment to strengthening its manufacturing footprint across the healthcare industry.

Facility Specifications and Timeline

The new manufacturing facility spans 40,000 sq. ft. and is expected to become operational by October 2026. This expansion represents a strategic move to enhance the company's production capabilities and meet growing domestic and international demand across its diversified product portfolio.

Strategic Manufacturing Expansion

The facility will support key product categories including veterinary products, supportive nutraceuticals, and pharmaceutical formulations. The company has outlined several expected operational benefits from this expansion, including enhanced efficiency, improved production scalability, and the ability to meet growing market demand.

Additionally, Fredun Pharmaceuticals has planned a 50,000 sq. ft. expansion to be undertaken under strategic growth initiatives, further demonstrating its commitment to scaling operations. The integration with existing facilities is expected to strengthen the company's presence across pharmaceutical and nutraceutical sectors.

Management Commentary

Commenting on the development, Mr. Fredun Medhora, Managing Director, stated: "As our business continues to expand, we are gradually strengthening our manufacturing footprint to stay aligned with our requirements. With opportunities opening up across our key segments, our focus remains on building a stronger and more scalable foundation."

Company Profile and Financial Performance

Fredun Pharmaceuticals Limited operates as a healthcare and pharmaceuticals company offering a diverse range of products. The company's portfolio includes antihypertensives, antidiabetic medications, antiretroviral drugs (ARVs), and narcotics. It is also engaged in manufacturing dietary and herbal supplements, nutraceuticals, cosmeceuticals, and other healthcare products, along with animal healthcare products.

The company primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries, and Latin America. With such a diverse product range, the company positions itself as a holistic healthcare provider.

The opening of the fifth manufacturing facility aligns with the company's objective to maintain high standards of quality, compliance, and innovation while strengthening its position as a leading manufacturing partner in the healthcare industry.